First Turn Management LLC Has $30.47 Million Stock Position in Vera Therapeutics, Inc. $VERA

First Turn Management LLC lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 69.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 601,774 shares of the company’s stock after acquiring an additional 247,245 shares during the period. Vera Therapeutics makes up 3.5% of First Turn Management LLC’s portfolio, making the stock its 13th largest holding. First Turn Management LLC owned approximately 0.86% of Vera Therapeutics worth $30,474,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares in the last quarter. Optimize Financial Inc boosted its stake in Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after buying an additional 256 shares in the last quarter. Intech Investment Management LLC boosted its stake in Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after buying an additional 424 shares in the last quarter. Invesco Ltd. boosted its stake in Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after buying an additional 639 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total value of $679,690.00. Following the sale, the chief executive officer owned 216,744 shares in the company, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Up 1.8%

Shares of NASDAQ:VERA opened at $34.26 on Friday. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The company’s fifty day moving average is $37.02 and its 200-day moving average is $41.38. The company has a market capitalization of $2.46 billion, a PE ratio of -6.18 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business posted ($0.81) EPS. Equities research analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on VERA shares. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a research note on Wednesday, March 11th. Evercore set a $91.00 target price on shares of Vera Therapeutics in a research note on Friday, May 15th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.